Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in NVO — Novo Nordisk A S

CIK 1423053 MIAMI, FL
Back to NVO Full portfolio

Position in NVO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$65,499,223
-$35,068,070 QoQ
Shares Held
1,366,275
-50.1% QoQ
Ownership
0.031%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#47
of 1,348 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVO Over Time

Shares Held

Position Value (USD)

Derivatives in NVO

reported options exposure · as of Jun 30, 2026
CallValue
$434,307,636
CallShares
9,059,400
PutValue
$423,377,316
PutShares
8,831,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $3,979,998,649 across 21 Drug Manufacturers - General names. NVO ranks #12 (1.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 945,456 $1,134,008,383
2 ABBV
AbbVie Inc.
 3,169,783 $797,644,194
3 GILD
Gilead Sciences, Inc.
 3,480,444 $439,719,294
4 JNJ
Johnson & Johnson
 1,500,832 $381,166,302
5 AMGN
Amgen Inc
 703,984 $254,926,685
6 MRK
Merck & Co., Inc.
 1,933,667 $248,476,209
7 AZN
Astrazeneca PLC
 970,043 $183,939,553
8 PFE
Pfizer Inc
 6,191,186 $149,083,758

All Filings in NVO

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $434,307,636 9,059,400
2026-06-30 $423,377,316 8,831,400
2026-06-30 $65,499,223 1,366,275
2026-03-31 $100,567,293 2,736,525
2026-03-31 $351,686,475 9,569,700
2026-03-31 $287,877,450 7,833,400
2025-12-31 $414,951,840 8,155,500
2025-12-31 $377,067,762 7,410,923
2025-12-31 $782,905,824 15,387,300
2025-09-30 $173,796,566 3,132,034
2025-09-30 $337,795,375 6,087,500
2025-09-30 $579,226,816 10,438,400
2025-06-30 $27,364,497 396,472
2025-06-30 $202,622,014 2,935,700
2025-06-30 $267,556,030 3,876,500
2025-03-31 $163,031,232 2,347,800
2025-03-31 $119,325,556 1,718,398
2025-03-31 $242,748,352 3,495,800
2024-12-31 $54,283,522 631,057
2024-12-31 $196,400,864 2,283,200
2024-12-31 $212,598,430 2,471,500
2024-09-30 $137,371,059 1,153,700
2024-09-30 $49,014,093 411,641
2024-09-30 $159,887,196 1,342,800
2024-06-30 $124,627,150 873,106
2024-06-30 $200,863,728 1,407,200
2024-06-30 $254,476,872 1,782,800
2024-03-31 $124,397,001 968,824
2024-03-31 $174,136,080 1,356,200
2024-03-31 $254,617,200 1,983,000
2023-12-31 $120,043,380 1,160,400
2023-12-31 $96,549,885 933,300
2023-12-31 $55,387,853 535,407
2023-09-30 $89,994,224 989,600
2023-09-30 $29,861,604 328,366
2023-09-30 $100,606,922 1,106,300
2023-06-30 $83,536,646 516,200
2023-06-30 $35,298,359 218,120
2023-06-30 $75,574,610 467,000
2023-03-31 $58,102,014 365,100
2023-03-31 $60,377,716 379,400
2023-03-31 $36,601,403 229,995
2022-12-31 $55,651,808 411,200
2022-12-31 $54,920,700 405,798
2022-12-31 $34,268,088 253,200
2022-09-30 $30,234,217 303,465
2022-09-30 $42,791,085 429,500
2022-09-30 $34,322,535 344,500
2022-06-30 $20,235,688 181,600
2022-06-30 $49,497,428 444,202

Report a Problem

Category
Description
Email (optional, for follow-up)